Navigation Links
Bowel disease link to blood clots
Date:2/10/2010

People living with Inflammatory Bowel Disease (IBD) are known to be at high risk of blood clots when admitted to hospital during a flare-up of their disease but now new research by scientists at The University of Nottingham has shown that those who are not admitted to hospital during flare-ups are also at risk.

The two main types of IBD are Ulcerative Colitis and Crohn's Disease which affect about one in every 250 people in the UK. The research published today in the medical journal, The Lancet, could eventually mean new advice for GPs and patients on how to reduce the risk of developing this dangerous side-effect of bowel disease.

IBD has been known to predispose sufferers to blood clots (thromboembolism) for some time. Clots in the leg veins have a mortality rate of six per cent, rising to as much as 20 per cent if the embolism is in the lungs. Previous research has suggested that most patients who develop thromboembolism do so when their IBD is 'active', i.e. has flared up and they are three times more likely to have a blood clot than non-sufferers. This has led to the use of anti-clotting drugs

The new research at Nottingham was undertaken to find out what the blood-clotting risk is to patients with IBD who manage their flare-ups outside the hospital environment, with medical care from primary care sources like their GP. The team used the UK General Practice Research Database from November 1987 to July 2001 to compare patients with IBD with controls without the disease. They concluded that non-hospitalised sufferers with active IBD were 16 times more likely to develop a blood clot than the general population.

In detail, the researchers analysed 13,756 patients with IBD and 71,672 matched controls, and of these, 139 patients and 165 controls developed a blood clot. Overall, patients with IBD were almost three and a half times more likely to have a blood clot than the controls. At the time of a flare-up however, this increase in risk was much more prominent (eight times). Although the absolute risk of clots was greater for patients in hospital, this relative risk at the time of a flare-up was higher during non-hospitalised periods (when patients were at 16 times the risk of their non-hospitalised controls) than during hospitalised periods (when the risk was three times that of other hospitalised patients).

Dr Matthew Grainge, Lecturer in the University's Department of Community Health Sciences said:

"Inflammatory bowel disease was associated with a roughly three-fold increase in the risk of venous thromboembolism. Compared with the general population while ambulatory, the risk of venous thromboembolism was increased about 16-fold for non-hospitalised patients with active inflammatory bowel disease. Despite the low absolute risks during non-hospitalised periods, these results suggest that active inflammatory bowel disease in ambulatory patients might be a far greater risk factor for venous thromboembolism than previously recognised."

Dr Grainge's co-researcher, Dr Tim Card concluded:

"We believe that the medical profession needs to recognise the increased risk in people with inflammatory bowel disease when assessing the likelihood of venous thromboembolism and to address the difficulty of reducing this risk in patients with a flare who are not admitted to hospital... Such strategies to achieve a reduction in risk might include those used for inpatients such as brief courses of low-molecular weight heparin or perhaps newly available oral anticoagulants."

Commenting on the research, Dr Geoffrey C Nguyen, Mount Sinai Hospital Inflammatory Bowel Disease Centre, University of Toronto, Canada, and Johns Hopkins Division of Gastroenterology and Hepatology, Baltimore, MD, USA; and Dr Erik L Yeo, University Health Network Thrombosis Clinic, University of Toronto, Canada, said:

"We believe that the clinical efficacy and cost-effectiveness of pharmacological prophylaxis in the population with inflammatory bowel disease should be proven before it is routinely recommended during acute flares. The ascertainment of efficacy data through clinical trials might, however, be a formidable challenge given that the absolute risk of venous thromboembolism is low and a sample size of thousands of people with inflammatory bowel disease during active flares might be required.

"A pragmatic initial approach to reduction of the rates of morbidity and mortality resulting from venous thromboembolism in ambulatory patients with inflammatory bowel disease would be non-pharmacological thromboprophylaxis, including patients' education and awareness of risk and signs and symptoms of venous thromboembolism, and use of support stockings."


'/>"/>

Contact: Emma Rayner
emma.rayner@nottingham.ac.uk
44-011-595-15793
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Jarrow Formulas, Inc. to Unveil Ideal Bowel Support (IBS) 299v at Upcoming Natural Products Expo West Show in Anaheim
3. Bacterial phylotype alterations in irritable bowel syndrome
4. St. Johns wort not helpful treatment for irritable bowel syndrome, Mayo Clinic researchers say
5. Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases
6. Bowel Disease Treatment May Raise Skin Cancer Risk
7. Drugs for Inflammatory Bowel Might Increase Cancer Risk
8. Drugs for Irritable Bowel Might Increase Cancer Risk
9. Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
10. Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US
11. Soluble Fiber, But Not Bran, Soothes Irritable Bowel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... FRANCISCO AND TEL AVIV (PRWEB) , ... June ... ... 3D-imaging sensor company whose technology makes it possible to see through objects, has ... challenging makers to create consumer apps with its fully programmable, Raspberry Pi-enabled 3D ...
(Date:6/28/2017)... ... June 28, 2017 , ... Drs. Steven Crandall, Karen ... treatment in Pittsburgh, PA, and Upper St. Clair, PA, without a referral. The doctors ... restoring the health of the temporomandibular joint and facial muscles that support it. ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... ... 2017 , ... Schneider Insurance and Financial, a Yellowstone County ... Montana, is announcing a focused charity effort to gather regional support for the ... Zoo Montana provide students with current knowledge on the characteristics and behaviors of ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly ... to survey data released today by the American Society for Dermatologic Surgery ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled since ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... that it will be presenting at the 7th annual LD Micro ... Erez Raphael , CEO, of DarioHealth will be giving the presentation ... on June 6th & 7th, 2017 at the Luxe Sunset Bel ... micro-cap space. About LD Micro ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: